Beranda › Leukemia Sel B
Uji klinis Leukemia Sel B yang merekrut di AS
17 studi untuk Leukemia Sel B merekrut peserta di lokasi di seluruh Amerika Serikat.
Kota dengan studi terbanyak
- Houston, TX7 studi
- Dallas, TX5 studi
- Washington, DC5 studi
- Columbus, OH4 studi
- Portland, OR4 studi
- Philadelphia, PA3 studi
- Pittsburgh, PA3 studi
- Charlotte, NC3 studi
- Clifton, NJ3 studi
- Boston, MA3 studi
- Edison, NJ3 studi
- New York City, NY3 studi
- Louisville, KY3 studi
- Spokane, WA3 studi
- Denver, CO3 studi
- San Diego, CA3 studi
- Chicago, IL3 studi
Berdasarkan negara bagian
- California7 studi
- Colorado3 studi
- Florida3 studi
- Illinois4 studi
- Kansas3 studi
- Kentucky3 studi
- Maryland5 studi
- Massachusetts3 studi
- Minnesota3 studi
- New Jersey4 studi
- New York4 studi
- North Carolina5 studi
- Ohio7 studi
- Oregon4 studi
- Pennsylvania5 studi
- Texas12 studi
- Washington5 studi
Studi yang baru diperbarui
Teks studi resmi (Bahasa Inggris)
CD19/CD22 Bicistronic Chimeric Antigen Receptor (CAR) T Cells in Children and Young Adults With Recurrent or Refractory B Cell Malignancies
Menerima pesertaFase 1/2
Usia 3 hingga 39 · Semua jenis kelamin · Diperbarui 30 Sep 2026 · NCT05442515A Study to Evaluate Safety, PK, PD and Efficacy of AZD5492, a T Cell-engaging Antibody Targeting CD20 in Subjects With R/R B-Cell Malignancies.
Menerima pesertaFase 1/2
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 30 Sep 2026 · NCT06542250Natural History Study of Monoclonal B Cell Lymphocytosis (MBL), Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL), Lymphoplasmacytic Lymphoma (LPL)/Waldenstrom Macroglobulinemia (WM), and Splenic Marginal Zone Lymphoma (SMZL)
Menerima pesertaStudi observasional
Usia 18 hingga 110 · Semua jenis kelamin · Diperbarui 28 Sep 2026 · NCT00923507Efficacy and Safety of Nemtabrutinib (MK-1026) in Participants With Hematologic Malignancies (MK-1026-003)
Menerima pesertaFase 2
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 24 Sep 2026 · NCT04728893Acalabrutinib Monotherapy vs Investigator's Choice of Treatment in Patients With CL Leukaemia and Heart Failure
Menerima pesertaFase 4
Usia 18 hingga 130 · Semua jenis kelamin · Diperbarui 24 Sep 2026 · NCT06651970Chimeric Antigen Receptor Treatment Targeting CD70 (SEVENTY)
Menerima pesertaFase 1
Hingga usia 75 · Semua jenis kelamin · Diperbarui 16 Sep 2026 · NCT06345027A Study of AZD0486 Monotherapy or in Combination With Other Anti-Cancer Agents for Mature B-Cell Malignancies
Menerima pesertaFase 1/2
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 8 Sep 2026 · NCT06564038Surovatamig as Consolidation Therapy in Participants With Chronic Lymphocytic Leukaemia or Small Lymphocytic Lymphoma With Unmutated Immunoglobulin Heavy Chain Variable (IGHV)
Menerima pesertaFase 3
Usia 18 hingga 18 · Semua jenis kelamin · Diperbarui 8 Sep 2026 · NCT07509151Trivalent CAR-T Cell in Acute B-Lineage Leukemia (TRICAR-ALL)
Menerima pesertaFase 1
12 Months – 25 Years · Semua jenis kelamin · Diperbarui 4 Sep 2026 · NCT05010564Caloric Restriction and Activity to Reduce Chemoresistance in B-ALL
Menerima pesertaFase 2
Usia 7 hingga 25 · Semua jenis kelamin · Diperbarui 19 Agu 2026 · NCT05082519A Study of Pirtobrutinib (LOXO-305) Versus Ibrutinib in Participants With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)
Menerima pesertaFase 3
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 17 Agu 2026 · NCT05254743ROCKET-CLL Global Phase 3 Study: Rocbrutinib vs Pirtobrutinib in cBTKi-Pretreated R/R CLL/SLL
Menerima pesertaFase 3
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 11 Agu 2026 · NCT07342478A Study of Lonitoclax (ZE50-0134) in Relapsed or Refractory B-cell Malignancies
Menerima pesertaFase 1
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 31 Jul 2026 · NCT06708897The OPAL Study: AVM0703 for Treatment of Lymphoid Malignancies
Menerima pesertaFase 1/2
Usia 12 hingga 95 · Semua jenis kelamin · Diperbarui 15 Apr 2026 · NCT04329728A Platform Protocol to Investigate Post-Transplant Cyclophosphamide-Based Graft-Versus-Host Disease Prophylaxis in Patients With Hematologic Malignancies Undergoing Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation
Menerima pesertaFase 2
Usia 18 hingga 66 · Semua jenis kelamin · Diperbarui 17 Mar 2026 · NCT06859424A Multi-site Study to Evaluate the Persistence of Protective Immunity to Routine Childhood Vaccinations in Participants With B-ALL/Ly Who Have Received Blinatumomab
Menerima pesertaStudi observasional
Usia 1 hingga 23 · Semua jenis kelamin · Diperbarui 25 Feb 2026 · NCT07422337Transgene Assay Testing Service of Tumor Samples From Patients Who Received a Bristol-Myers Squibb Manufactured Gene Modified Cell Therapy and Have a Qualifying Second Primary Malignancy
Menerima pesertaStudi observasional
Semua usia · Semua jenis kelamin · Diperbarui 22 Jan 2026 · NCT06357754Dari ClinicalTrials.gov, data diambil 2 Okt 2026. Setiap studi menetapkan kriteria kelayakannya sendiri; tim studi yang menentukan siapa yang bisa bergabung.